698 results found

On July 18 the Federal Circuit in Cardex, Inc. v. Eurofins Viracor, Inc., affirmed the district court decision finding that diagnostic method claims directed to detecting organ...

On June 3, 2021, the ITC released the public version (see Part I, Part II, Part III, Part IV) of the final initial determination ("ID") issued by ALJ Clark S. Cheney finding a violation of section 337...

On Thursday, June 16, 2022, Senators Patrick Leahy (D-VT), Thom Tillis (R-NC), and John Cornyn (R-TX) introduced the Patent Trial and Appeal Board (PTAB) Reform Act of 2022 (PTAB Reform Act).

Following up on my post last week (Dec 1.), I have read commentary about how the Federal Circuit's decision in Biogen v. Mylan was incorrect.

The Federal Circuit in a precedential opinion in Osai Pharmaceuticals, LLC v Apotex et al (Fed. Cir., October 4, 2019) reversed the USPTO's determination of obviousness...

On Tuesday the Federal Circuit vacated its decision in GlaxoSmithKline LLC. V. Teva Parma., USA, Inc., 976 F.3d 1347 (Fed. Cir. 2020) in response to GSK's request for rehearing en banc.

Defendants then moved for an award of attorneys' fees of approximately $600,000.

On March 31, 2021, ALJ Dee Lord issued a notice of initial determination ("ID") in Certain Lithium-Ion Battery Cells, Battery Modules, Battery Packs, Components Thereof, and Products Containing the...

ALJ McNamara found 18 respondents in default in Order Nos. 35, 62, 63, and 64.

In denying the petition for rehearing en banc the majority of the Federal Circuit abdicated its responsibility to define the limits of the Supreme Court's Mayo decision.

On August 29, 2022, the Federal Circuit released a modified version* of its precedential opinion in Best Medical Int'l, Inc. v. Elekta, Inc.

When it comes to IPR petitions filed in the Bio/Pharma space, USPTO data tells us that while Bio/Pharma petitions make up only 8% of the total petitions filed for the fiscal year of 2022 (through June 30, 2022)...

On July 27, 2021, the ITC issued the public version of its opinion finding no violation of section 337 in Certain Mobile Devices with Multifunction Emulators.

Previously, ADT filed for inter partes review of Applied's ‘817 patent, challenging the validity of the patent's claims for obviousness.

On May 17, 2024, the Patent Trial and Appeal Board (PTAB) affirmed a rejection of a claim directed to a purification method using single-domain antigen-binding proteins...

The USPTO has launched a new Covid-19 Prioritized Examination Pilot Program to help small and micro entities. The USPTO will accept requests for prioritized examination of up to 500 qualifying patent applications without requiring ...

On January 5, 2021, Samsung Electronics Co., Ltd. of Korea and Samsung Electronics America, Inc. of Ridgefield Park, New Jersey (collectively, "Samsung") filed a complaint requesting that the ITC commence an investigation pursuant to Section 337.